Equity Profile

BHC

Bausch Health Companies Inc.

Health CarePharmaceuticals$2.0B

Jul29Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Bausch Health Companies Inc. (BHC) operates in the health care sector, focusing on pharmaceuticals....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$0.78

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, crucial for long-term sustainability.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BHC Q2-2026 Earnings Preview

Context

Company Snapshot

Bausch Health Companies Inc. (BHC) operates in the health care sector, focusing on pharmaceuticals. The company is significant due to its diverse portfolio of products aimed at addressing various medical needs, which can impact healthcare costs and patient outcomes.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-77.46%

Avg Stock Reaction

-1.15%

Last Quarter Recap

In Q1-2026, Bausch Health reported an EPS of $0.78, which was slightly below the expected $0.81, resulting in a minor stock decline of 1.41% the following day. The company has struggled to meet earnings expectations in recent quarters.

Management Promises & Guidance

Focus on improving product pipeline and operational efficiency.
Commitment to reducing debt levels.
Plans to enhance marketing strategies for key products.

Expectations

Wall Street Expectations

Overall, expectations for Bausch Health's upcoming earnings are cautious, given its recent history of missing estimates. Investors are looking for signs of improvement in profitability and revenue.

Bull Case

If Bausch Health can exceed EPS expectations and show signs of revenue growth, it may regain investor confidence and see a positive stock reaction.

Bear Case

Conversely, if the company continues to miss earnings estimates and fails to provide a clear path to recovery, it could lead to further declines in stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.78

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

N/A

Revenue growth reflects the company's ability to expand its market presence and sales, crucial for long-term sustainability.

Market Reaction to Earnings

N/A

Understanding how the stock reacts to earnings can provide insights into investor sentiment and market expectations.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Bausch Health achieve an EPS of $0.78 or higher?

This specific EPS target is crucial as it will indicate whether the company is making progress in its profitability efforts.

What are the revenue figures for key product lines?

Understanding revenue performance in key areas will help gauge the company's market position and growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Bausch Health's potential for a turnaround, as recent product launches could drive unexpected revenue growth.

Supporting Evidence

Options are pricing in a larger move than historical averages suggest, indicating potential for a surprise.

Management's commitment to debt reduction may not be fully reflected in current valuations.

The company's diverse product portfolio could mitigate risks associated with individual product performance.

Key Risk

If revenue from key products exceeds expectations, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Bausch Health can turn around its recent performance and regain investor trust.

Bull Confirmed If

An EPS of $0.80 or higher would confirm a positive outlook and suggest effective management strategies.

Bear Confirmed If

An EPS below $0.75 would indicate ongoing struggles and could lead to further stock declines.

Pre-Earnings Positioning

Options Market

Implied Move

±13.32%

Historical Avg

±2.9%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings announcement.

Options are pricing ±13.3% while BHC has averaged ±2.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

32.3%

Calls (64K)P/C Ratio: 0.10Puts (21K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bausch Health beats expectations, history suggests the stock could rise by around 3.6%, confirming a recovery narrative.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further clarity from management.

Miss

A miss on earnings could lead to a decline of about 1.15%, reinforcing negative sentiment around the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the performance of new product launches.
2Any guidance on debt reduction progress.
3Insights into market share changes in key therapeutic areas.
4Management's commentary on competitive pressures.
5Future plans for R&D investments.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

Insider activity

PreviewView

Jul

Company Snapshot

Bausch Health Companies Inc. (BHC) operates in the health care sector, focusing on pharmaceuticals....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$0.78

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and sales, crucial for long-term sustainability.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BHC Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

Avg EPS Surprise

-77.46%

Avg Stock Reaction

-1.15%

Last Quarter Recap

Management Promises & Guidance

Focus on improving product pipeline and operational efficiency.
Commitment to reducing debt levels.
Plans to enhance marketing strategies for key products.

Expectations

Wall Street Expectations

Overall, expectations for Bausch Health's upcoming earnings are cautious, given its recent history of missing estimates. Investors are looking for signs of improvement in profitability and revenue.

Bull Case

If Bausch Health can exceed EPS expectations and show signs of revenue growth, it may regain investor confidence and see a positive stock reaction.

Bear Case

Conversely, if the company continues to miss earnings estimates and fails to provide a clear path to recovery, it could lead to further declines in stock price.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.78

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue Growth

N/A

Revenue growth reflects the company's ability to expand its market presence and sales, crucial for long-term sustainability.

Market Reaction to Earnings

N/A

Understanding how the stock reacts to earnings can provide insights into investor sentiment and market expectations.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Bausch Health achieve an EPS of $0.78 or higher?

This specific EPS target is crucial as it will indicate whether the company is making progress in its profitability efforts.

What are the revenue figures for key product lines?

Understanding revenue performance in key areas will help gauge the company's market position and growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Bausch Health's potential for a turnaround, as recent product launches could drive unexpected revenue growth.

Supporting Evidence

Options are pricing in a larger move than historical averages suggest, indicating potential for a surprise.

Management's commitment to debt reduction may not be fully reflected in current valuations.

The company's diverse product portfolio could mitigate risks associated with individual product performance.

Key Risk

If revenue from key products exceeds expectations, it could significantly shift market sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Bausch Health can turn around its recent performance and regain investor trust.

Bull Confirmed If

An EPS of $0.80 or higher would confirm a positive outlook and suggest effective management strategies.

Bear Confirmed If

An EPS below $0.75 would indicate ongoing struggles and could lead to further stock declines.

Pre-Earnings Positioning

Options Market

Implied Move

±13.32%

Historical Avg

±2.9%

Pricing rich

The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings announcement.

Options are pricing ±13.3% while BHC has averaged ±2.9% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

32.3%

Calls (64K)P/C Ratio: 0.10Puts (21K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bausch Health beats expectations, history suggests the stock could rise by around 3.6%, confirming a recovery narrative.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction as investors await further clarity from management.

Miss

A miss on earnings could lead to a decline of about 1.15%, reinforcing negative sentiment around the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the performance of new product launches.
2Any guidance on debt reduction progress.
3Insights into market share changes in key therapeutic areas.
4Management's commentary on competitive pressures.
5Future plans for R&D investments.